TickerGuard
Buy Day today: Neutral (47) Mixed market breadth · no major macro event
ROIV

Roivant Sciences Ltd

Healthcare · Biotechnology

34.80$ -2.2% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ROIV
Line item 2019 2020 2021 2022 2023 2024 2025 2026
– +78.5% +8.6% -3.9% -7.6% +202.2% -24.7% +5.4%
– +87.2% -1.5% -1.9% -16.2% +274.3% -25.7% +3.3%
– +157.3% -2.4% -3.4% -18.6% +289.8% -58.5% -47.6%
– +157.3% -2.4% -3.4% -18.4% +288.9% -25.3% -12.1%
– +39.3% -9.5% -51.3% +459.2% +120.0% – –
– – +6,386,899,900.0% -125.8% – +1,176.7% – –
– +565.4% +4.2% -66.4% +50.9% – – –
– – – – – -4.9% – –
– -18.2% +43.3% -0.8% +49.3% -1.0% -67.7% +74.4%
– -56.4% +137.7% -15.8% +47.8% -2.1% -44.0% +88.2%
– -63.0% +57.1% -7.4% +359.8% -58.2% -55.0% +13.3%
– +65.3% +99.4% +68.3% +9.4% +40.7% -55.5% -24.0%
– – – +23.3% +78.8% +14.7% – –
– +116.8% -6.6% -12.7% -30.1% +415.5% -21.5% -3.4%
– – – – – – -79.9% -532.4%
– +218.0% +0.0% -2.2% +6.4% +16.6% -12.7% -4.3%

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?